CARBOPLATIN

INDICATION (ICD10) C50, C54, C56

1. Triple negative or BRCA mutated metastatic breast cancer (case based discussion).
2. Frontline chemotherapy in ovarian carcinoma.
3. Relapsed (non-refractory) ovarian carcinoma who have not relapsed during 1st line platinum based chemotherapy.
4. Endometrial carcinoma.
5. Serous papillary uterine cancer

PS 0, 1, 2

REGIMEN

Day 1	**CARBOPLATIN**	AUC* 5	IV infusion	#ml glucose 5% over 30 minutes

*Dose calculated by EDTA GFR or calculated (CrCl + 25) x AUC.
Non-breast indications - maximum dose when using CrCl (125+25 x AUC)mg
Breast cancer - maximum dose when using CrCl is 700mg

diluent volume for dose prescribed as per national standardised product specification

CYCLE FREQUENCY AND NUMBER OF CYCLES

Non-ovarian - every 21 days for 6 cycles
Ovarian - every 21 days for 6 cycles (an additional 2 cycles may be given following debulking surgery ie up to 8 cycles)

ANTI-EMETICS

Moderate risk day 1

CONCURRENT MEDICATION REQUIRED

Carboplatin	Anaphylaxis treatment should be prescribed if the patient has had an anaphylactic episode previously. Dexamethasone 20mg IV bolus Chlorphenamine 10mg IV bolus H_2 antagonist Carboplatin should be given at a slower rate e.g. 2-4 hours.

EXTRAVASATION AND TYPE OF LINE / FILTERS

Carboplatin - irritant

Filter not required
Peripheral or central line

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E including Mg^{++} (>0.4) and LFTs Neutrophils $x10^9$/L ≥1.5 (breast patients) Neutrophils $x10^9$/L ≥1.0 provided patient is well (gynae patients) Platelets $x10^9$/L ≥100	baseline and every cycle
GFR assessed using EDTA result (BMI <19 or >30 (gynae patients) or calculated creatinine clearance at the Consultant's discretion	baseline and every cycle
Serum creatinine patients with hydronephrosis or serum creatinine ≥100micromol/L	baseline and every cycle
CA125 (gynae patients)	baseline and day 1 every cycle
Virology	before cycle 1 if not previously checked
Weight	baseline and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Carboplatin	Ototoxicity – monitor Neurotoxicity - monitor

DOSE MODIFICATIONS

Hepatic impairment

Carboplatin

No need for dose adjustment is expected

Renal impairment

Carboplatin

GFR/ calculated CrCl ≤20ml/min or ≤30ml/min with pre-existing severe renal impairment	contraindicated

REFERENCES

1. Tutt A, et al: The TNT trial. 2014 San Antonio Breast Cancer Symposium. Abstract S3-01. Presented December 11, 2014.
2. The Lancet Oncology Volume 15, No. 7, p747–756, November 2014
3. Prof Gunter von Minckwitz, MD, Prof Andreas Schneeweiss, MD, Prof Sibylle Loibl, MD, Christoph Salat, MD, Prof Carsten Denkert, MD, Prof Mahdi Rezai, MD, Prof Jens U Blohmer, MD, Prof Christian Jackisch, MD, Stefan Paepke, MD, Prof Bernd Gerber, MD, Dirk M Zahm, MD, Sherko Kümmel, MD, Holger Eidtmann, MD, Peter Klare, MD, Prof Jens Huober, MD, Prof Serban Costa, MD, Prof Hans Tesch, MD, Claus Hanusch, MD, Prof Jörn Hilfrich, MD, Fariba Khandan, MD, Prof Peter A Fasching, MD, Bruno V Sinn, MD, Knut Engels, MD, Keyur Mehta, MBA, Valentina Nekljudova, PhD, Prof Michael Untch, MD Published Online: 30 April 2014
4. Taylor, AE, E Wiltshaw, et al, Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. *J Clin Oncol*, 1994 12(10): p2066-70.
5. Colombo, N., D. Guthrie, et al., International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst*, 2003. 95(2): p125-32.
6. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. *Lancet*, 1998. 352(9140): p1571-6.
7. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin

or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet*, 2002. 360(9332): p505-15.
8. Parmar, M.K., J.A. Ledermann, et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet*, 2003. 361(9375): p2099-106.

Assessments

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Ongoing
Clinical assessment	X		Pre cycle		Pre cycle	Every cycle
SACT assessment (PS and toxicities)	X	X	X	X	X	Every cycle
FBC	X	X	X	X	X	Every cycle
U&E, calcium, magnesium & LFT	X	X	X	X	X	Every cycle
CrCl	X	X	X	X	X	Every cycle
CT scan	X					At cycle 6, Inform consultant team if not booked
Informed consent	X					Verbal each cycle
Height	X					
Weight recorded	X	X	X	X	X	Every cycle